Premium
Immunofluorescence and confocal microscopy for ex‐vivo diagnosis of melanocytic and non‐melanocytic skin tumors: A pilot study
Author(s) -
Hartmann Daniela,
Krammer Sebastian,
Vural Secil,
Bachmann Mario Raphael,
Ruini Cristel,
Sárdy Miklós,
Ruzicka Thomas,
Berking Carola,
von Braunmühl Tanja
Publication year - 2018
Publication title -
journal of biophotonics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 66
eISSN - 1864-0648
pISSN - 1864-063X
DOI - 10.1002/jbio.201700211
Subject(s) - ex vivo , immunostaining , in vivo , pathology , staining , confocal microscopy , immunofluorescence , confocal , immunohistochemistry , medicine , biomedical engineering , biology , antibody , immunology , microbiology and biotechnology , geometry , mathematics
Background Ex‐vivo confocal laser scanning microscopy (ex‐vivo CLSM) offers rapid examination of freshly excised tissue. During the conventional examination immunohistochemistry enables to distinguish various cell types. The possibility of immunofluorescent techniques could enhance the accuracy of the diagnosis performed by ex‐vivo CLSM. Methods The tissue probes from various skin tumors were stained with FITC‐labeled S‐100A10, Melan‐A and anti‐Ber‐EP4 antibodies before examination with ex‐vivo CLSM in the fluorescence and reflectance modes. Results were compared to negative controls and conventional histopathology. The staining protocols were evaluated by establishing a scoring system according to the signal intensity found in ex‐vivo CLSM. Results S100 immunostaining was successful in 55.6%. Dilution of 1:200 resulted in the best possible evaluation of the tumor. The best suitable protocol was protocol B (phosphate buffered saline [PBS], without blocking agent). Melan A immunostaining was positive in 66.7%, the best dilution was 1:500 and protocol B (PBS, without blocking agent) was the most suitable. Ber‐EP4 immunostaining presented a signal in 85.7%, the best dilutions were 1:200 and 1:500 and protocol A (PBS, with blocking agent) showed most optimal results. Conclusion The use of fluorescent‐labeled antibodies in ex‐vivo CLSM is possible and could improve intraoperative diagnostics of skin tumors.